ELLKF yields 35.31% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 9
Combined, ELLKF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ELLKF + JNJ for your $10,000?
Ellaktor S.A., through its subsidiaries, engages in the construction and quarrying, wind energy, concession, environment, and real estate development businesses in Greece, other European countries, Gulf countries, the Americas, and Australia. The company operates through five segments: Construction, Concessions, Renewable Energy Sources (RES), Environment, and Real estate Development. It constructs bridges, motorways, metro projects, biological treatment plants, natural gas pipelines, refineries, shopping centers, casinos, tourist and hotel units, cultural centers, hospitals, airports, Olympic and athletic complexes, railway projects, tunnels, dams, port projects, energy production stations, electromechanical projects, etc.; and logistics, office, residential, industrial, and educational buildings. The company is also involved in the waste management and energy production, which include design, construction, and operation of waste treatment plant, as well as offers alternative fuel production and biomass exploitation projects. In addition, it develops, constructs, and operates wind farms; provides real estate development and services, which consists of retail parks, entertainment centers, residential complexes, exhibition centers, and offices and mixed use buildings, as well as offers consultancy and services to third parties. The company was formerly known as ELLINIKI TECHNODOMIKI TEB SA and changed its name to Ellaktor S.A. in 2008. The company is headquartered in Athens, Greece.
Full ELLKF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.